Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 14/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504216 | 0.86 | CA12 (0.46) | TYK2ALDH1A1 | |
| SCHEMBL4536908 | 0.85 | ALDH1A1 (0.63) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL18713609 | 0.85 | TYK2 (0.55) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL5463408 | 0.83 | TYK2 (0.54) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL9635722 | 0.83 | TYK2 (0.54) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL29932942 | 0.83 | TYK2 (0.54) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL9525419 | 0.83 | TYK2 (0.54) | TYK2RORCCYP2C9CYP3A4PPARG | |
| SCHEMBL23908702 | 0.82 | ALDH1A1 (0.51) | TYK2ALDH1A1 | |
| SCHEMBL18671762 | 0.80 | TYK2 (0.51) | TYK2RORCCYP2C9CYP3A4PPARG | |
| Trifluoroacetic Acid SCHEMBL3979025 | 0.80 | ALDH1A1 (0.50) | TYK2ALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023016530-A1 | 3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE COMPOUNDS AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2023-02-16 | — | — | WO | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | disclosed |
| WO-2021150574-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-1477482-A1 | NOVEL PHENYLALANINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004024738-A1 | METHOD FOR METAL-ORGANIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS BY MEANS OF ARYL LITHIUM-BASES | CLARIANT GMBH (DE) | 2004-03-25 | — | — | WO | disclosed |
| CN-1469867-A | Novel phenylalanine derivatives | ֮����ʽ���� | 2004-01-21 | — | — | CN | disclosed |
| US-20030220318-A1 | New phenylalanine derivatives | AJINOMOTO CO. INC (JP) | 2003-11-27 | — | — | US | disclosed |
| US-20030220268-A1 | New phenylalanine derivatives | AJINOMOTO CO. INC (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1323711-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1288205-A1 | NOVEL PHENYLALANINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-4125620-A | HYPOTENSIVE | BOEHRINGER INGELHEIM GMBH (DE) | 1978-11-14 | — | — | US | disclosed |
| US-3985799-A | 2-Fluoro-6-trifluoromethylbenzoic acid | SANDOZ, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3985799-A | 2-Fluoro-6-trifluoromethylbenzoic acid | SANDOZ, INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220318-A1 | New phenylalanine derivatives | VCAM1, PAH, ICAM1 | TYK2 121/4885RORC 1339/4885CYP2C9 3559/4885 |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | TYK2 4120/4885RORC 3835/4885CYP2C9 1177/4885 |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TYK2 587/4885RORC 648/4885CYP2C9 2814/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | TYK2 387/4885RORC 1253/4885CYP2C9 1079/4885 |
| US-20030220268-A1 | New phenylalanine derivatives | ITGB4, ITGA4, ITGB3 | TYK2 627/4885RORC 3223/4885CYP2C9 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.